Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability

Clinical and Translational Science

Volumn 1, Issue 2, 2008, Pages 142-145

  Mann, Douglas L ^a   Bozkurt, Biykem ^a   Torre Amione, Guillermo ^b   Soran, Ozlem Z ^c   Sivasubramanian, Natarajan ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Heart failure; Soluble tumor necrosis factor antagonist; Tumor necrosis factor

Indexed keywords

ETANERCEPT; PLACEBO; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; HEART FAILURE; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STABILITY;

HEART FAILURE; HUMANS; IMMUNOGLOBULIN G; PROTEIN STABILITY; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449333577     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2008.00013.x     Document Type: Article

References (13)

1. Lorenz HM, Kalden JR. Perspectives for TNF-alpha-targeting therapies. Arthritis Res. 2002; 4 (Suppl. 3): S17-S24.
2. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003; 138: 807-811.
3. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-{alpha}, in patients with moderate-to-severe heart failure: Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003; 107: 3133-3140.
4. Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, Dijan J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anti-cytokine therapy in patients with chronic heart failure: Results of the Randomized Etancercept worldwide evaluation (RENEWAL). Circulation. 2004; 109: 1594-1602.
5. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, Mann DL. Results of targeted ant-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001; 103: 1044-1047.
6. Kapadia S, Torre-Amione G, Yokoyama T, Mann DL. Soluble tumor necrosis factor binding proteins modulate the negative inotropic effects of TNF-α in vitro. Am J Physiol. 1995; 37: H517-H525.
7. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol. 1995; 155: 5038-5045.
8. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, Schroeder DR. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003; 124: 177-185.
9. Mohler KM, Torrance DS, Smiht CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993; 151: 1548-1561.
10. Soran O, Feldman AM, Schneider VM, Hanna R, Mann DL, Korth-Bradley JM. The pharmacokinetics of etanercept in patients with heart failure. Br J Clin Pharmacol. 2001; 51: 191-192.
11. Evans TJ, Moyes D, Carpenter A, Martin R, Loetscher H, Lesslauer W, Cohen J. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. JEM. 1994; 180: 2173-2179.
12. Frishman JI, Edwards CK III, Sonnenberg MG, Kohno T, Cohen AM, Dinarello CA. Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. J Infect Dis. 2000; 182: 1722-1730.
13. Fisher Jr. CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Study Group. N Engl J Med. 1996; 334: 1697-1702.